Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tomorrow might give an indication as to what the heck happened friday
NDA applies only to the specifics of the patent, not the filing or application number.
What is scaring me is they could have filed any type of patent they wanted for free and called it a covid patent and then EXACTLY THIS HAPPENS.
Not good news reverse split several times this year, last year, ...
Corporate Actions Reverse Split
Symbol Changes
ACTION TYPE EFFECTIVE DATE SYMBOL DESCRIPTION
Symbol Change 05/01/2020 SBFM Symbol change from SBFMD to SBFM
Symbol Change 04/06/2020 SBFM Symbol change from SBFM to SBFMD
Symbol Change 03/01/2019 SBFM Symbol change from SBFMD to SBFM
Symbol Change 02/01/2019 SBFM Symbol change from SBFM to SBFMD
Symbol Change 04/05/2010 SBFM Symbol change from SBFME to SBFM
Company has never confirmed patent with a application or filing number and many asked several times!!!
Only thing I've read is patent not denied, but NOT approved either and the emails from the administration basically state nothing is wrong.
Does not give me relief in their response. I Hate to say that and emotions here are quite high and tense...Everything I read and saw on Friday tells like something bad has happened with the patent and maybe it can be fixed??
Tomorrow we see if recover or screwed :(
They should update the float! Doesn't correspond with the billion O/S
All is great after a massive dump? Yes something missing about that AND positive for the company!
Deflected.
Down 40..lots of venting today..
Nobody is to blame except company
“ the company is in good shape and nothing is wrong at all. “
Camilles response does not sit well with me. Look how much we are down
What did Camille say about the jerk?
SBFM patent FDA approval covid-19 vaccine and anti cancer drug
Board link:
https://investorshub.advfn.com/Sunshine-Biopharma-Inc-SBFM-14329/
This is showing up on a google search of Sunshine Biopharma SBFM and their recently filed covid-19 patent that was filed on May 22, 2020 along with their FDA application for covid-19.
SBFM Completes Synthesis of Covid-19 Inhibitors Protease! (8/25/20)
https://marketwirenews.com/news-releases/sunshine-biopharma-completes-the-synthesis-of-four-p-4594537033321571.html
SBFM has reduced their OS by 78M confirmed on OTCMarkets!!!
SBFM performed a share buy back in August of 2020 (confirmed on OTCMarkets & most recent 10-Q filing)
That is a 28% reduction in the Outstanding Shares as of 8/19/2020.
DTC registered shares puts the actual available shares at 185M.
From the 10-Q posted 8/19/2020
The number of shares of the registrant’s only class of Common Stock issued and outstanding as of August 18, 2020, was 200,308,644 shares.
https://sec.report/Document/0001654954-20-009340/
https://sec.report/Ticker/SBFM
Market Cap 5,248,086 08/26/2020
Outstanding Shares 200,308,644 08/18/2020
Restricted 11,154 08/04/2020
Unrestricted 278,408,142 08/04/2020
Held at DTC 263,916,517 08/04/2020
SBFM patent FDA approval covid-19 vaccine and anti cancer drug
Board link:
https://investorshub.advfn.com/Sunshine-Biopharma-Inc-SBFM-14329/
This is showing up on a google search of Sunshine Biopharma SBFM and their recently filed covid-19 patent that was filed on May 22, 2020 along with their FDA application for covid-19.
SBFM Completes Synthesis of Covid-19 Inhibitors Protease! (8/25/20)
https://marketwirenews.com/news-releases/sunshine-biopharma-completes-the-synthesis-of-four-p-4594537033321571.html
SBFM has reduced their OS by 78M confirmed on OTCMarkets!!!
SBFM performed a share buy back in August of 2020 (confirmed on OTCMarkets & most recent 10-Q filing)
That is a 28% reduction in the Outstanding Shares as of 8/19/2020.
DTC registered shares puts the actual available shares at 185M.
From the 10-Q posted 8/19/2020
The number of shares of the registrant’s only class of Common Stock issued and outstanding as of August 18, 2020, was 200,308,644 shares.
https://sec.report/Document/0001654954-20-009340/
https://sec.report/Ticker/SBFM
Market Cap 5,248,086 08/26/2020
Outstanding Shares 200,308,644 08/18/2020
Restricted 11,154 08/04/2020
Unrestricted 278,408,142 08/04/2020
Held at DTC 263,916,517 08/04/2020
$SBFM covid19 coronavirus BioPharma stock with patents and fda.
Today had lots of weird 4900 trades. What are those?
SBFM has reduced their OS by 78M confirmed on OTCMarkets!!!
OS: 200M
https://www.otcmarkets.com/stock/SBFM/security
Patent submission was also updated!!
https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2897768/images.html?modificationDate=20200021&page=1&scale=25&rotation=0&frenchDocType=Modification&englishDocType=Amendment&type=basic_search&objectName=A1001001A20H25B03057G27576&numPages=11&query=sunshine+biopharma&start=&num=#archived
SBFM has reduced their OS by 78M confirmed on OTCMarkets!!!
OS: 200M
https://www.otcmarkets.com/stock/SBFM/security
Patent submission was also updated!!
https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2897768/images.html?modificationDate=20200021&page=1&scale=25&rotation=0&frenchDocType=Modification&englishDocType=Amendment&type=basic_search&objectName=A1001001A20H25B03057G27576&numPages=11&query=sunshine+biopharma&start=&num=#archived
SBFM has already begun to synthesis pharmaceuticals
That may give SBFM the green light.
Small amendment before final processing, approval and disposition?
That's patent attorneys for ya :)
Patent site has update for SBFM!
Update is as of 8/21
https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2897768/images.html?modificationDate=20200021&page=1&scale=25&rotation=0&frenchDocType=Modification&englishDocType=Amendment&type=basic_search&objectName=A1001001A20H25B03057G27576&numPages=11&query=sunshine+biopharma&start=&num=#archived
SBFM has an update on their patent!
https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2897768/images.html?modificationDate=20200021&page=1&scale=25&rotation=0&frenchDocType=Modification&englishDocType=Amendment&type=basic_search&objectName=A1001001A20H25B03057G27576&numPages=11&query=sunshine+biopharma&start=&num=#archived
SBFM has a patent update!
THAT IS HUGE NEWS!!!!!!!!!!!!!
Thanks
SBFM Completes Synthesis of Covid-19 Inhibitors Protease! BREAKING NEWS
https://marketwirenews.com/news-releases/sunshine-biopharma-completes-the-synthesis-of-four-p-4594537033321571.html
MONTREAL, QC / ACCESSWIRE / August 25, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in the Company's recently filed patent application covering small molecules which can be used to treat Coronavirus infections, including SARS-CoV-2 the causative agent of COVID-19. Next, Sunshine will evaluate the binding affinity of these molecules to the SARS-CoV-2 papain-like protease (PLpro), one of two virus encoded proteases essential for viral replication. In addition to cleaving the virus encoded polyprotein at three different sites to generate mature virus proteins, PLpro also cleaves certain host proteins resulting in suppression of the innate immune response thereby allowing the virus to multiply unhindered. Based on the binding affinity results, Sunshine will select a lead compound for further Anti-Coronavirus drug development.
About Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, to working on the development of a treatment for COVID-19, Sunshine biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a and the Coronavirus protease inhibitors under development.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly
CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/603154/Sunshine-Biopharma-Completes-the-Synthesis-of-Four-Potential-Inhibitors-of-Coronavirus-Protease
SBFM Completes Synthesis of Covid-19 Inhibitors Protease! BREAKING NEWS
https://marketwirenews.com/news-releases/sunshine-biopharma-completes-the-synthesis-of-four-p-4594537033321571.html
MONTREAL, QC / ACCESSWIRE / August 25, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in the Company's recently filed patent application covering small molecules which can be used to treat Coronavirus infections, including SARS-CoV-2 the causative agent of COVID-19. Next, Sunshine will evaluate the binding affinity of these molecules to the SARS-CoV-2 papain-like protease (PLpro), one of two virus encoded proteases essential for viral replication. In addition to cleaving the virus encoded polyprotein at three different sites to generate mature virus proteins, PLpro also cleaves certain host proteins resulting in suppression of the innate immune response thereby allowing the virus to multiply unhindered. Based on the binding affinity results, Sunshine will select a lead compound for further Anti-Coronavirus drug development.
About Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, to working on the development of a treatment for COVID-19, Sunshine biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a and the Coronavirus protease inhibitors under development.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly
CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/603154/Sunshine-Biopharma-Completes-the-Synthesis-of-Four-Potential-Inhibitors-of-Coronavirus-Protease
SBFM Completes Synthesis of Covid-19 Inhibitors Protease! BREAKING NEWS
https://marketwirenews.com/news-releases/sunshine-biopharma-completes-the-synthesis-of-four-p-4594537033321571.html
MONTREAL, QC / ACCESSWIRE / August 25, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in the Company's recently filed patent application covering small molecules which can be used to treat Coronavirus infections, including SARS-CoV-2 the causative agent of COVID-19. Next, Sunshine will evaluate the binding affinity of these molecules to the SARS-CoV-2 papain-like protease (PLpro), one of two virus encoded proteases essential for viral replication. In addition to cleaving the virus encoded polyprotein at three different sites to generate mature virus proteins, PLpro also cleaves certain host proteins resulting in suppression of the innate immune response thereby allowing the virus to multiply unhindered. Based on the binding affinity results, Sunshine will select a lead compound for further Anti-Coronavirus drug development.
About Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, to working on the development of a treatment for COVID-19, Sunshine biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a and the Coronavirus protease inhibitors under development.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly
CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/603154/Sunshine-Biopharma-Completes-the-Synthesis-of-Four-Potential-Inhibitors-of-Coronavirus-Protease
SBFM RETIRES 78M shares! O/S is 200M after SHARE BUY BACK last week!
That is a 28% reduction in the Outstanding Shares as of 8/19/2020.
DTC registered shares puts the actual available shares at 185M.
From the 10-Q posted 8/19/2020
The number of shares of the registrant’s only class of Common Stock issued and outstanding as of August 18, 2020, was 200,308,644 shares.
https://sec.report/Document/0001654954-20-009340/
https://sec.report/Ticker/SBFM
SBFM is a Covid-19 & FDA play with two priority and fast track submissions with the FDA and US Patent office for their covid-19 vaccine and treatment!
On May 22, 2020, SBFM filed for FDA approval and US Patent.
Sunshine Biopharma Files A Patent Application For A New Coronavirus COVID-19 Treatment
https://finance.yahoo.com/news/sunshine-biopharma-files-patent-application-130000935.html
SBFM is also in the process or distributing generic products by Astrazeneca!
The following drugs will or are available by SBFM:
Anastrozole (brand name Arimidex® by AstraZeneca) for treatment of Breast Cancer
Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer
Bicalutamide (brand name Casodex® by AstraZeneca) for treatment of Prostate Cancer
Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia)
See previous 10-Q, mentioning the generics:
https://sec.report/Document/0001654954-20-005714/
and SBFM's press release
https://sunshinebiopharma.com/press-releases.html
https://sunshinebiopharma.com/drugs-market.html
SBFM RETIRES 78M shares! O/S is 200M after SHARE BUY BACK last week!
That is a 28% reduction in the Outstanding Shares as of 8/19/2020.
DTC registered shares puts the actual available shares at 185M.
From the 10-Q posted 8/19/2020
The number of shares of the registrant’s only class of Common Stock issued and outstanding as of August 18, 2020, was 200,308,644 shares.
https://sec.report/Document/0001654954-20-009340/
https://sec.report/Ticker/SBFM
SBFM is a Covid-19 & FDA play with two priority and fast track submissions with the FDA and US Patent office for their covid-19 vaccine and treatment!
On May 22, 2020, SBFM filed for FDA approval and US Patent.
Sunshine Biopharma Files A Patent Application For A New Coronavirus COVID-19 Treatment
https://finance.yahoo.com/news/sunshine-biopharma-files-patent-application-130000935.html
SBFM is also in the process or distributing generic products by Astrazeneca!
The following drugs will or are available by SBFM:
Anastrozole (brand name Arimidex® by AstraZeneca) for treatment of Breast Cancer
Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer
Bicalutamide (brand name Casodex® by AstraZeneca) for treatment of Prostate Cancer
Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia)
See previous 10-Q, mentioning the generics:
https://sec.report/Document/0001654954-20-005714/
and SBFM's press release
https://sunshinebiopharma.com/press-releases.html
https://sunshinebiopharma.com/drugs-market.html
Slilaty owns 50% of the Class B preferred shares. That gives him a majority in voting shares. He owns 50% of the Class B, (500,000) out of 1M Class B voting shares. The company eliminated the Class A shares in an earlier AoI amendment.
If someone bought 101M shares, they would own a controlling stake in SBFM using common shares. It is impossible to own more than what you said.
500,000 is not greater than 3,000,000,000.
Outstanding Shares in SBFM is presently 200M, with approximately 185M registered with the DTC. This is the most current share structure according to the 10-Q released last week on 8/18.
Math 101
They reduced the OS 78M in the 10-q last week!
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
[X] No
The number of shares of the registrant’s only class of Common Stock issued and outstanding as of August 18, 2020, was 200,308,644 shares.
This after SBFM announced a reduced OS and share buyback
Lots of swirling rumours SBFM has a buy out/merger occurring with uplisting!!!!
SBFM RELEASED 10Q TODAY, OS reduced 73M to 200M, Sharebuyback!
From the 10-Q posted TODAY 8/19/2020
The number of shares of the registrant’s only class of Common Stock issued and outstanding as of August 18, 2020, was 200,308,644 shares.
https://sec.report/Document/0001654954-20-009340/
https://sec.report/Ticker/SBFM
SBFM is also in the process or distributing generic products by Astrazeneca!
The following drugs will or are available by SBFM:
Anastrozole (brand name Arimidex® by AstraZeneca) for treatment of Breast Cancer
Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer
Bicalutamide (brand name Casodex® by AstraZeneca) for treatment of Prostate Cancer
Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia)
See previous 10-Q, mentioning the generics:
https://sec.report/Document/0001654954-20-005714/
and SBFM's press release
https://sunshinebiopharma.com/press-releases.html
https://sunshinebiopharma.com/drugs-market.html
From today's 10-Q
The number of shares of the registrant’s only class of Common Stock issued and outstanding as of August 18, 2020, was 200,308,644 shares.
O/S reduced 73million!!! There were rumors of a share buy back..Did this really occur?!?!??!
10-Q out and is it wonderful!
https://sec.report/Document/0001654954-20-009340/
.04 is in my sites
...which means its gonna pop!!! Even more!
MMs been holding this with tons of BUYS!! going through...
80% more buys on the trade today